{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"202","value":"303"},{"groupId":"OG001","spread":"1570","value":"1890"},{"groupId":"OG002","spread":"1550","value":"3620"},{"groupId":"OG003","spread":"4510","value":"8880"},{"groupId":"OG004","spread":"8040","value":"17000"},{"groupId":"OG005","spread":"13000","value":"41000"},{"groupId":"OG006","spread":"19300","value":"117000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"title":"cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"163","value":"753"},{"groupId":"OG001","spread":"225","value":"1520"},{"groupId":"OG002","spread":"3280","value":"5620"},{"groupId":"OG003","spread":"7740","value":"14300"},{"groupId":"OG004","spread":"18400","value":"29400"},{"groupId":"OG005","spread":"27900","value":"77800"},{"groupId":"OG006","spread":"32900","value":"163000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"title":"cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"80.2","value":"895"},{"groupId":"OG001","spread":"318","value":"1780"},{"groupId":"OG002","spread":"2850","value":"5110"},{"groupId":"OG003","spread":"13200","value":"17900"},{"groupId":"OG004","spread":"28500","value":"42200"},{"groupId":"OG005","spread":"17700","value":"84600"},{"groupId":"OG006","spread":"165000","value":"282000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"}],"units":"Participants"}],"title":"cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.6","value":"785"},{"groupId":"OG002","spread":"2420","value":"9150"},{"groupId":"OG003","spread":"13100","value":"19600"},{"groupId":"OG004","spread":"26500","value":"43400"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"cycle 6"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"2190","value":"10200"},{"groupId":"OG003","spread":"10600","value":"21600"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"cycle 7"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"description":"To evaluate the Cmin of INCAGN01949 in subjects with advanced or metastatic solid tumors. Cmin is the minimum observed concentration of INCAGN1949","dispersionType":"Standard Deviation","groups":[{"description":"INCAGN01949 7mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG000","title":"PART 1 Dose 1 (7 mg)"},{"description":"INCAGN01949 20mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG001","title":"PART 1 Dose 2 (20 mg)"},{"description":"INCAGN01949 70mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG002","title":"PART 1 Dose 3 (70 mg)"},{"description":"INCAGN01949 200mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG003","title":"PART 1 Dose 4 (200 mg)"},{"description":"INCAGN01949 350mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG004","title":"PART 1 Dose 5 (350 mg)"},{"description":"INCAGN01949 700mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG005","title":"PART 1 Dose 6 (700 mg)"},{"description":"INCAGN01949 1400mg administered intravenously over a 30-minute period on Day 1 of each cycle in subjects with advanced or metastatic solid tumors","id":"OG006","title":"PART 1 Dose 7 (1400 mg)"}],"paramType":"MEAN","populationDescription":"The PK evaluable population will include all subjects who received at least 1 dose of INCAGN01949 and provided at least 1 post dose sample (1 PK measurement).","reportingStatus":"POSTED","timeFrame":"Pre-infusion for cycles 1,2,3,4,5,6 and 7, 10-minutes, 4 hrs, 24 hrs post-infusion, Day 8 for cycles 1 & 6","title":"Summary of Trough Concentrations(Cmin) of INCAGN01949","type":"SECONDARY","unitOfMeasure":"ng/mL"}